Ping An Biomedical holds extraordinary general meeting
PASW•Ping An Biomedical shareholders approved a 40-for-1 share consolidation effective October 23, 2026, and authorized increasing share capital from US$312,500 to US$12.5 million. They also approved possible further consolidations of 10-for-1, 20-for-1, 50-for-1 or 80-for-1, subject to specified share-price triggers.
1. Meeting approvals
At an extraordinary general meeting on October 29, 2026, Ping An Biomedical shareholders ratified a 40-for-1 share consolidation that took effect on October 23. They also approved increasing authorized share capital from US$312,500 to US$12.5 million.
2. Further consolidations
Shareholders approved possible additional consolidations at ratios of 10-for-1, 20-for-1, 50-for-1 or 80-for-1, subject to specified share-price triggers. Adoption of amended articles reflecting the capital increase or any further consolidation is conditional on the relevant change taking effect.
